Correlated Drug Terms (0)

---

	Name (Synonyms)	Correlation

Correlated MeSH Terms (2)

---

	Name (Synonyms)	Correlation
D045169	Severe Acute Respiratory Syndrome NIH	0.05
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Any adverse event, serious adverse event (SAE) occurred during the clinical study, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs will be observed for all the subjects, the their clinical manifestations and features, severity, time to onset, end time, therapeutic measures and outcomes will be recorded, and the correlation of the adverse events with the investigational product will be judged

Measure: Correlation of adverse events with the investigational product

Time: 12 Weeks

---

Secondary Outcomes

Description: Area under the curve from the time of dosing to the last measurable concentration time t (AUC0-last);

Measure: Primary pharmacokinetic variables

Time: 12 Weeks

---

Description: Maximum concentration (Cmax);

Measure: Primary pharmacokinetic variables

Time: 12 Weeks

---

Description: Mean residence time (MRT)

Measure: Primary pharmacokinetic variables

Time: 12 Weeks

---

Description: Terminal half life (t1/2);

Measure: Primary pharmacokinetic variables

Time: 12 Weeks

---

Other Outcomes

Description: Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time (AUC0-∞);

Measure: pharmacokinetic

Time: 12 Weeks

---

Description: Time to maximum concentration (Tmax);

Measure: pharmacokinetic

Time: 12 Weeks

---

Description: Clearance (CL);

Measure: pharmacokinetic

Time: 12 Weeks

---

Description: Apparent terminal elimination rate constant (λz)

Measure: pharmacokinetic

Time: 12 Weeks

---

Description: Apparent volume of distribution (Vd)

Measure: pharmacokinetic

Time: 12 Weeks

---